James M. Hoffman, Pharm.D., M.S., B.C.P.S. is an Associate Member in Pharmaceutical Sciences and the Medication Outcomes & Safety Officer at St. Jude Children's Research Hospital. He is also an associate professor at the University of Tennessee College of Pharmacy. He earned both his undergraduate and doctoral degree from the Philadelphia College of Pharmacy at the University of the Sciences in Philadelphia. He completed a M.S. degree at the University of Wisconsin-Madison, and training at the University of Wisconsin Hospital and Clinics. His primary interests include medication safety, clinical decision support, and the clinical implementation of pharmacogenetics.
PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics
Article first published online: 11 MAR 2014
© 2014 Wiley Periodicals, Inc.
American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Special Issue: Implementation of Genomic Medicine
Volume 166, Issue 1, pages 45–55, March 2014
How to Cite
2014. PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet Part C Semin Med Genet 166C:45–55., , , , , , , , , , , , , .
Conflict of Interest: Dr. Mary V. Relling and Dr. William E. Evans receive royalties from licensing TPMT genotyping, Prometheus Labs.
* Correspondence to: James M. Hoffman, St. Jude Children's Research Hospital, Pharmaceutical Sciences Department, 262 Danny Thomas Place MS #150, Memphis, TN 38105. E-mail: firstname.lastname@example.org
- Issue published online: 18 MAR 2014
- Article first published online: 11 MAR 2014
- NCI. Grant Numbers: CA 36401, CA 21765
- NIH/NIGMS Pharmacogenomics Research Network. Grant Numbers: U01 GM92666, UO1 HL105918
- The American Lebanese Syrian Associated Charities (ALSAC)
- 2013. Personal genomic measurements: The opportunity for information integration. Clin Pharmacol Ther 93:21–23. .
- 2013. Challenges in the pharmacogenomic annotation of whole genomes. Clin Pharmacol Ther 94:211–213. , , .
- 2014. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 21:e93–9. , , , , , , , , , , , , , , .
- 2006. Acute lymphoblastic leukaemia: A model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 6:117–129. , .
- 2008. Incidental findings in genetics research using archived DNA. J Law Med Ethics 36:286–291. .
- 2011a. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91:321–326. , , , , , , , .
- 2011b. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 68:143–150. , , , , , , , .
- 2003. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538–549. , .
- 1999. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487–491. , .
- 2013. A health-care system perspective on implementing genomic medicine: Pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther 94:224–229. , , .
- 2012. Concordance of DMET Plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther 92:360–365. , , , , , , , , , , , , , .
- 2011. Charting a course for genomic medicine from base pairs to bedside. Nature 470:204–213. , .
- 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15:565–574. , , , , , , , , , , , , , .
- 2012. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 92:563–566. , , , , , , , , , , , , , , , , .
- 2013. Clinical implementation of pharmacogenetics: More than one gene at a time. Clin Pharmacol Ther 93:384–385. , , .
- 2011. Genomics reaches the clinic: From basic discoveries to clinical impact. Cell 147:14–16. , .
- 2004. Pharmacogenetics-decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5:669–676. .
- 2012. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 92:87–95. , , , , , , , , , , , , , , , , , , , , .
- 2011. CPIC: Clinical Pharmacogenetics Implementation Consortium of the pharmacogenomics research network. Clin Pharmacol Ther 89:464–467. , .
- 2006. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107:843–844. , , , .
- 2013. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 93:324–325. , , , , , , , , , , , .
- 2013. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update. Clin Pharmacol Ther 94:317–323. , , , , , , , , , .
- 2013. The Pharmacogenomics Research Network translational pharmacogenetics program: Overcoming challenges of real-world implementation. Clin Pharmacol Ther 94:207–210. , , , , , , , , .
- 2010. Clinical pharmacology and pharmacogenetics in a genomics era: The DMET platform. Pharmacogenomics 11:89–103. , , , , .
- 2011. Pharmacogenetics: From bench to byte-an update of guidelines. Clin Pharmacol Ther 89:662–673. , , , , , , , , , , , , , .
- 2010. A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice. Genet Med 12:686–693. , , , , .
- 2011. Institutional Profile: A hub for bench-to-bedside pharmacogenomic-based research. Pharmacogenomics 12:1095–1098. , .
- 2011. Genomics and drug response. N Engl J Med 364:1144–1153. , , .
- 2012. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 92:112–117. , , , , , , , , , , , , , .
- 2008. Managing incidental findings in human subjects research: Analysis and recommendations. J Law Med Ethics 36:219–248. , , , , , , , , , , , , , , , , , , , , .